Cargando…

Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1 (PD-1) blockade, have proven to be the most effective agents for the management of many cancer types. Although ICIs are the current standard of care for treating metastatic clear cell renal cell carcinoma (c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jee, ByulA, Seo, Eunjeong, Park, Kyunghee, Kim, Yi Rang, Byeon, Sun-ju, Lee, Sang Min, Chung, Jae Hoon, Song, Wan, Sung, Hyun Hwan, Jeon, Hwang Gyun, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Park, Se Hoon, Park, Woong-Yang, Kang, Minyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139776/ https://www.ncbi.nlm.nih.gov/pubmed/35625960 http://dx.doi.org/10.3390/cancers14102354

Ejemplares similares

Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Lee, Ji Hyun, et al.
Publicado: (2023)

Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma
por: Kim, Yeon Jeong, et al.
Publicado: (2021)

Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis
por: Kang, Minyong, et al.
Publicado: (2020)

Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor–Resistant Clear Cell Renal Cell Carcinoma()
por: Jang, Jiryeon, et al.
Publicado: (2017)

Role of Adjuvant Chemotherapy in Advanced Stage Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: Competing Risk Analysis after Propensity Score-Matching
por: Kang, Minyong, et al.
Publicado: (2019)

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
por: Byeon, Seonggyu, et al.
Publicado: (2021)

TRUS-Guided Target Biopsy for a PI-RADS 3–5 Index Lesion to Reduce Gleason Score Underestimation: A Propensity Score Matching Analysis
por: Chung, Jae Hoon, et al.
Publicado: (2022)

Assessment of Agreement between Two Difference Prostate-Specific Antigen Assay Modalities
por: Chung, Jae Hoon, et al.
Publicado: (2021)

Conditional Intravesical Recurrence-Free Survival Rate After Radical Nephroureterectomy With Bladder Cuff Excision for Upper Tract Urothelial Carcinoma
por: Chung, Jae Hoon, et al.
Publicado: (2021)

The clinical utility of transperineal template-guided saturation prostate biopsy for risk stratification after transrectal ultrasound-guided biopsy
por: Song, Wan, et al.
Publicado: (2019)

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study
por: Hur, Joon Young, et al.
Publicado: (2019)

A Comparison of Functional and Oncologic Outcomes between Partial Nephrectomy and Radiofrequency Ablation in Patients with Chronic Kidney Disease after Propensity Score Matching
por: Ryoo, Hyunsoo, et al.
Publicado: (2022)

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma
por: Jo, Hyunji, et al.
Publicado: (2022)

New transperineal ultrasound-guided biopsy for men in whom PSA is increasing after Miles’ operation
por: Park, Byung Kwan, et al.
Publicado: (2023)

Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL)
por: Chung, Jae Hoon, et al.
Publicado: (2020)

Robotic Radical Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma: A Trend Analysis of Utilization and a Comparative Study
por: Bae, Hoyoung, et al.
Publicado: (2022)

Comparison of Prostate-Specific Antigen and Its Density and Prostate Health Index and Its Density for Detection of Prostate Cancer
por: Boo, Youngjun, et al.
Publicado: (2023)

Utility of multiple core biopsies during transperineal template-guided mapping biopsy for patients with large prostates and PI-RADS 1–2 on multiparametric magnetic resonance imaging
por: Lee, Chung Un, et al.
Publicado: (2022)

Correlation between Gleason score distribution and Prostate Health Index in patients with prostate-specific antigen values of 2.5–10 ng/mL
por: Choi, Joongwon, et al.
Publicado: (2020)

Risk factors for prostate-specific antigen persistence in pT3aN0 prostate cancer after robot-assisted laparoscopic radical prostatectomy: a retrospective study
por: Kim, Jun Seop, et al.
Publicado: (2023)

Clinical Significance of Pre-to-Postoperative Dynamics of Aspartate Transaminase/Alanine Transaminase Ratio in Predicting the Prognosis of Renal Cell Carcinoma after Surgical Treatment
por: Kang, Minyong, et al.
Publicado: (2020)

Preoperative versus Postoperative Compensation of the Contralateral Normal Kidney in Patients Treated with Radical Nephrectomy for Renal Cell Carcinoma
por: Lee, Chung-Un, et al.
Publicado: (2021)

Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2021)

Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels
por: Bang, Seokhwan, et al.
Publicado: (2021)

Incidences and oncological outcomes of urothelial carcinoma in kidney transplant recipients
por: Yu, Jiwoong, et al.
Publicado: (2018)

Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions
por: Lee, Chung-Un, et al.
Publicado: (2022)

Prostate-specific antigen kinetics in hypofractionated radiation therapy alone for intermediate- and high-risk localized prostate cancer
por: Lee, Tae Hoon, et al.
Publicado: (2023)

Comparison of Risk Factors for the Development of Proteinuria After Radical Nephrectomy for Renal Cell Carcinoma
por: Lee, Chung Un, et al.
Publicado: (2021)

Correction: Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value
por: Chung, Jae Hoon, et al.
Publicado: (2022)

Comparison of oncologic and functional outcomes between radical nephroureterectomy and segmental ureterectomy for upper urinary tract urothelial carcinoma
por: Kim, Tae Heon, et al.
Publicado: (2021)

The Role of Prostate Combination Biopsy Consisting of Targeted and Additional Systematic Biopsy
por: Lee, Chung Un, et al.
Publicado: (2021)

Effects of Complete Bladder Cuff Removal on Oncological Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
por: Ryoo, Hyunsoo, et al.
Publicado: (2021)

Genomic analysis of Korean patients with advanced prostate cancer by use of a comprehensive next-generation sequencing panel and low-coverage, whole-genome sequencing
por: Kang, Minyong, et al.
Publicado: (2019)

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Predictors of postoperative complications after robot-assisted radical cystectomy with extracorporeal urinary diversion
por: Lee, Chung Un, et al.
Publicado: (2019)

Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy
por: Choi, Young Hyo, et al.
Publicado: (2019)

Utility of Contemporary Health Screening in the Diagnosis of Bladder Cancer
por: Lee, Chung-Un, et al.
Publicado: (2022)

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
por: Byeon, Seonggyu, et al.
Publicado: (2020)

A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
por: Kim, Hae Su, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9k50ebb9kqc4e79g9dm1nd19fr